A Case-Based Approach to Lipids Management: Individualizing Targets and Reducing Risk

AMA Accreditation Statement

The Association of Black Cardiologists is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
 

AMA Designation Statement
The Association of Black Cardiologists designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AANP Accreditation statement

National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 1.0 contact hour of continuing education which includes 0.50 pharmacology hours.

Funding Statement

This activity is supported by educational funding provided by Amgen.

Introduction

Low density cholesterol (LDL-C) is causally associated with risk for cardiovascular disease, which is a common cause of morbidity and mortality. Lipid-lowering therapy can not only lower serum cholesterol but can also decrease adverse cardiovascular events and mortality. Statins have been the mainstay of hypercholesteremia management for many years, but despite the use of these agents, cardiovascular event rates remain relatively high, underpinning the need for novel therapies. High risk patients, such as those with familial hypercholesterolemia (FH), a disorder associated with a mutation in the gene coding for proprotein convertase subtilisin/kexin type 9 (PCSK9), can particularly benefit from newer therapies. This activity will discuss the latest ACC/AHA Guidelines, examine non-statin therapy for secondary prevention, and how to overcome barriers for PCSK9 monoclonal antibody therapy.

Planning Committee

Gregg Sherman, MD

National Association for Continuing Education

Plantation, FL

Sandy Bihlmeyer, M.Ed.

National Association for Continuing Education

Plantation, FL

Michelle Frisch, MPH, CHCP

National Association for Continuing Education

Plantation, FL

Sheila Lucas, CWEP

National Association for Continuing Education

Plantation, FL

Joshua F. Kilbridge

President and Creative Director

Kilbridge Associates       

San Francisco, CA

Deborah Paschal, CRNP

Clinical Nurse Practitioner

Philadelphia, PA

James Underberg, MD, MS, FACPM, FACP

Lipidology & Cardiovascular Disease Prevention

Clinical Assistant Professor of Medicine

NYU Medical School & NYU Center for CV Prevention

Director, Bellevue Hospital Lipid Clinic

Past President National Lipid Association

New York, NY

Disclosure Policy Statement

It is the policy of ABC and NACE to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. NACE assesses conflict of interest with its faculty, planners and managers of CME activities. Conflicts of interest that are identified are resolved by reviewing that presenter's content for fair balance and absence of bias, scientific objectivity of studies utilized in this activity, and patient care recommendations.

While ABC and NACE endeavors to review faculty content, it remains the obligation of each physician or other healthcare practitioner to determine the applicability or relevance of the information provided from this course in his or her own practice.

Disclosure of Conflicts of Interest:

Faculty

David Montgomery, MD, PhD, FACC serves as a speaker for Novartis.

Planning Committee

Gregg Sherman, MD has no relationships to disclose.

Sandy Bihlmeyer has no relationships to disclose.

Michelle Frisch has no relationships to disclose.

Sheila Lucas has no relationships to disclose.

Deborah Paschal, CRNP has no relationships to disclose.

Josh Kilbridge has no relationships to disclose.

James Underberg, MD, MS, FACPM, FACP serves on the speakers bureau for Amgen, Amarin, Alexion, Akcea, Regeneron, and Sanofi. Dr. Underberg serves on the advisory board for Amgen, Regeneron, Sanofi, Amarin, Alexion, Aegerion, and Akcea as well as a consultant for Amgen, Regeneron, Sanofi, Amarin, and Ambry.

DISCLOSURE OF UNLABELED USE

ABC and NACE require that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

DISCLAIMER

The opinions expressed during the educational activity are those of the faculty and do not necessarily represent the views of ABC and NACE. The information is presented for the purpose of advancing the attendees' professional development.

TO OBTAIN CME CREDITS

• Read the learning objectives and faculty disclosures.
• Participate in the activity.
• Complete the post-test and activity evaluation.
• Physicians who successfully complete the post-test and evaluation will receive CME credit.
• Nurse Practitioners who successfully complete the post-test and evaluation will receive AANP CE credit.
• You must score 60% or higher on the post-test to receive credit for this activity.
• All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.

ACKNOWLEDGEMENT

This activity is sponsored by the Association of Black Cardiologists and the National Association for Continuing Education.

If you have any questions regarding this activity, send an email to info@naceonline.com.

Copyright © 2019 National Association for Continuing Education. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of NACE is prohibited.

COURSE VIEWING REQUIREMENTS